Efficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials

Basit Öğe Kaydı
dc.contributor.authorTanriverdi, Lokman H.
dc.contributor.authorBarrett, Annie
dc.contributor.authorKalyanasundaram, Asanish
dc.contributor.authorZafar, Mohammad A.
dc.contributor.authorZiganshin, Bulat A.
dc.contributor.authorElefteriades, John A.
dc.date.accessioned2026-04-04T13:34:45Z
dc.date.available2026-04-04T13:34:45Z
dc.date.issued2025
dc.departmentİnönü Üniversitesi
dc.description.abstractObjective: Studies investigating the efficacy of beta-blocker agents for patients with thoracic aortic aneurysm (TAA) have produced heterogeneous and conflicting results. We assess the effects of beta-blockers on clinical outcomes in patients with TAA. Methods: A systematic literature search was performed through Ovid MEDLINE, EMBASE, Web of Science, Pubmed and Cochrane CENTRAL, all from inception to April 30, 2024. Randomized controlled trials (RCTs) exploring the effect of beta-blocker agents in patients with TAA were considered for inclusion, with no population restriction. Inverse variance-weighted random-effects model was used. The overall risk of bias assessment was conducted by Cochrane Risk of Bias 2 tool. The primary outcome was aortic events during follow-up. Results: We included a total of 161 patients with TAA (mean age, 27.6 years; 80 [49.7 %] male, mean follow-up 6.7 years) in 4 RCTs. The pooled risk ratio in the beta-blocker arm for aortic events was 0.74 [95 % CI (0.20; 2.71), I-2: 0 %, p = 0.64, low certainty of evidence (CoE)] when compared to placebo or no treatment in patients with TAA. The pooled risk ratios for aortic dissection or death (all-cause mortality) or in the beta-blocker arm were 0.45 (95 % CI (0.10; 1.98), I-2: 0 %, p = 0.29, low CoE) and 0.58 (95 % CI (0.15; 2.24), I-2: 0 %, p = 0.43, low CoE), respectively. The risks of aortic dissection, rupture, or death were comparable, regardless of agent, disease, and age. Conclusion: We found no evidence of benefit from beta-blocker treatment for patients with TAA. More robust RCTs are needed to establish evidence-based recommendations.
dc.identifier.doi10.1016/j.vph.2025.107494
dc.identifier.issn1537-1891
dc.identifier.issn1879-3649
dc.identifier.orcid0000-0002-0698-9230
dc.identifier.orcid0000-0003-4263-5234
dc.identifier.orcid0000-0002-5190-4654
dc.identifier.orcid0000-0003-1666-199X
dc.identifier.pmid40204023
dc.identifier.scopus2-s2.0-105002038960
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1016/j.vph.2025.107494
dc.identifier.urihttps://hdl.handle.net/11616/109387
dc.identifier.volume159
dc.identifier.wosWOS:001482513900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofVascular Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectThoracic aortic aneurysm
dc.subjectMarfan syndrome
dc.subjectEhler-Danlos syndrome
dc.subjectbeta-blockers
dc.subjectPropranolol
dc.subjectAtenolol
dc.subjectCeliprolol
dc.titleEfficacy of beta-blocker agents on clinical outcomes in patients with thoracic aortic aneurysm: A systematic review and meta-analysis of randomized controlled trials
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu